Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYD Dengue Vaccine Booster in Adolescents and Adults
NCT02623725Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2016
- Primary completion
- Nov 2016
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, dengue hemorrhagic fever (DHF), sponsored by Sanofi. Started Apr 2016; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue feverdengue hemorrhagic fever (DHF)
Beyond the preview
Go deeper on NCT02623725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623725.